ASSESSMENT OF THE COMPARATIVE EFFICIENCY AND LONG-TERM RESULTS OF TREATMENT OF RHEUMATIC ARTHRITIS

Objective of the research: to assess the comparative efficiency and long-term results of treatment of rheumatic arthritis (RA).

Materials and methods: 80 RA patients have been examined. Of those, 40 patients (Group I) were administered with NSAIDs: Diclofenac 150 mg (daily dose), GCS: Prednisone 10 mg (daily dose), group II — 40 patients received NSAIDs, GCS and DMARDs: Methotrexate 10 mg (weekly dose). Dynamics of RA activity was assessed by DAS28 score at the beginning of the treatment course, then after 10 days, 6 months and 12 months, respectively, taking into account the radiological stage of the disease.

Results: a comparative study of the effectiveness of therapy in dynamics immediately after in-patient treatment showed a decrease of the DAS28 score: RA patients with X-ray stage 1 by 3,4% in group I (not treated with DMARDs) and 6,4% in the group II (treated with DMARDs), compared to their first day in the clinic; X-ray stage 2: group I — 4,2%, group II — 8,5%; X-ray stage 3: reduction in DAS28 index in both groups was approx 1,8%. After 6 months of treatment a decrease in DAS28 in patients with X-ray stage 1 amounted to 6,7% and 12,9%, X-ray stage 2 — 8,3% and 6,3%, X-Ray stage 3 — 1,8% and 6,8% for two groups, respectively. After 12 months of treatment a decrease in DAS28 in patients with X-ray stage 1 amounted to 10,0% and 22,5%, X-ray stage 2 — 12,5% and 14,9%, X-Ray stage 3 — 7,1% and 13,7% for both groups, respectively.

Conclusions: our research of the DMARDs effect on DAS28 score includes basic manifestations of immune and inflammatory process clearly showed the target effect of DMARDs on the rheumatoid process in dynamics of observation within 12 months. A study of the effectiveness of therapy in patients with RA showed significant efficacy of DMARDS in combination therapy with an analysis of the efficiency based on DAS28 score until stable remission of the disease.

1. Nasonov E.L., Karateev D.E. et al. Modern standards of pharmacotherapy of rheumatoid arthritis. Clinical Pharmacology and Therapeutics. 2005; 14(1): 72-75.

2. Zinchuk I.Y. Optimization of pharmaceutical care to patients with rheumatoid arthritis on the basis of pharmacoeconomic studies. Abstract of MD diss., M., 2013; 38 p.

3. American College of Rheumatology. Recommendations for the use of the basic anti-inflammatory drugs and biological agents in rheumatoid arthritis. Clinical Pharmacology and Therapeutics. 2009; 18(1): 38-44.

4. Konenkov V.I., Zonova M.A. Pharmacogenetic efficiency criteria of antiinflammatory therapy of rheumatoid arthritis. Therapeutic Archive. 2010; 12: 56-61.

5. Nasonov E.L., Lukin G.V., Sigidin Y.A. Prospects for the combination therapy of rheumatoid arthritis - leflunomide and genetically engineered biological agents. Clinical Pharmacology and Therapeutics. 2011; 20(1): 58-64.

6. Nasonov E.L. Pharmacotherapy for rheumatoid arthritis - a look at the 21st century. Clin. Medicine. 2005; 6: 8-12.

7. Nasonova V.A., Nasonov E.L., Alekperov R.T. et al. Rational pharmacotherapy of rheumatic diseases: a guide for practitioners. M.: Litterra, 2003; 507 p.

8. Revmatologija. Rheumatology. Clinical guidelines– ed. By E.L.Nasonova. M.: "GEOTAR-Media"publishing group. 2010; 752 p.

9. Zaliskaya O.N., Parnovskii B.L. Pharmacoeconomics: theoretical and practical areas of research. Provizor. 2000; 13: 32-34.

10. Van Vollenhoven R. Treatment of rheumatoid arthritis: state of the art 2009. Nat. Rev. Rheumatol. 2009; 6: 531-541.

11. Smolen J., Aletaha D., KoellrМ. et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370: 1861-1871.